Research analysts covering Nasus Pharma.
Recent press releases and 8-K filings for NSRX.
Nasus Pharma Announces Positive Interim Phase 2 Results for NS002
NSRX
- Nasus Pharma announced positive interim results from its Phase 2 clinical study of NS002 intranasal epinephrine powder for the treatment of anaphylaxis on January 20, 2026.
- The interim data indicated that NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen®, with 91% of study participants achieving the 100 pg/ml plasma threshold at 5 minutes compared to 67% with EpiPen®.
- NS002 was well-tolerated with no serious adverse events reported, and its pharmacodynamic response was comparable to EpiPen®.
- The company expects full Phase 2 results by the end of the first quarter of 2026 and plans to initiate a pivotal study in the fourth quarter of 2026.
Jan 20, 2026, 1:15 PM
Nasus Pharma Reports Increased Net Loss, Completes IPO, and Appoints New CFO
NSRX
Earnings
CFO Change
New Projects/Investments
- Nasus Pharma Ltd. reported a net loss of $(1,252) thousand for the six months ended June 30, 2025, an increase from $(871) thousand in the same period of 2024, and had an accumulated deficit of $13,916 thousand as of June 30, 2025. Management has concluded there is substantial doubt about the Company's ability to continue as a going concern due to expected continued losses and negative cash flow from operations.
- The company successfully completed an Initial Public Offering (IPO) in August 2025, raising approximately $10 million in gross proceeds. Following the IPO, the company's cash and cash equivalents increased to $4.2 million as of December 24, 2025, which management believes is sufficient for at least the next 12 months.
- Nasus Pharma initiated an additional Phase 2 clinical study for NS002 in Canada in November 2025, with interim results anticipated in the first quarter of 2026. Additionally, Mr. Eyal Rubin was appointed as Chief Financial Officer and Executive Vice President on November 19, 2025.
Dec 29, 2025, 1:00 PM
Nasus Pharma CEO Details 2025 Progress and 2026 Outlook
NSRX
New Projects/Investments
Guidance Update
- Nasus Pharma Ltd. successfully completed its initial public offering in August 2025, raising $10 million in gross proceeds, which strengthened the company's financial position.
- The company received authorization from Health Canada in October 2025 to initiate a planned Phase 2 clinical study for its lead product candidate, NS002, an intranasal epinephrine powder formulation, and subsequently dosed the first patient.
- Interim analysis from the Phase 2 study of NS002 is expected early in the first quarter of 2026, with a topline readout planned for the end of the first quarter of 2026.
- Key planned milestones for NS002 in 2026 include an Investigational New Drug (IND) submission and pivotal study initiation in the third quarter, and pediatric study initiation in the fourth quarter.
Dec 22, 2025, 1:15 PM
Nasus Pharma Appoints Eyal Rubin as Executive Vice President and CFO
NSRX
CFO Change
Management Change
Hiring
- Nasus Pharma Ltd. appointed Eyal Rubin as its Executive Vice President and Chief Financial Officer on November 19, 2025.
- Mr. Rubin will lead and oversee the company's financial operations, including corporate finance, financial planning, capital strategy, and investor relations.
- Prior to joining Nasus Pharma, Mr. Rubin served as Senior Vice President and CFO of Protalix BioTherapeutics, Inc. from September 2019 to October 2025, and held CFO and treasury roles at BrainStorm Cell Therapeutics Inc. and Teva Pharmaceutical Industries Ltd..
Nov 20, 2025, 1:30 PM
Nasus Pharma Initiates Phase 2 Clinical Study for NS002
NSRX
New Projects/Investments
- Nasus Pharma Ltd. announced the initiation of a Phase 2 clinical study for NS002, its investigational intranasal epinephrine powder formulation for anaphylaxis treatment, with the first participant dosed in Canada.
- The study is an open-label, fixed-sequence trial designed to evaluate the pharmacokinetic parameters and hemodynamic responses of NS002 compared to EpiPen in 50 healthy adults with a history of allergic rhinitis.
- Interim results from this Phase 2 study are expected in the first quarter of 2026.
- NS002 is being developed as a needle-free alternative to traditional epinephrine autoinjectors for anaphylaxis.
Nov 18, 2025, 1:15 PM
Nasus Pharma expands Aptar agreement for NS002 program
NSRX
New Projects/Investments
Product Launch
- Nasus Pharma Ltd. announced an expanded agreement with Aptar France S.A.S. and AptarGroup, Inc. on October 8, 2025, to support the development and commercialization of its NS002 intranasal epinephrine program.
- This collaboration provides Nasus Pharma with a commercially proven Unit Dose System technology, access to Aptar's technical expertise, manufacturing capabilities, and supply chain, aiming to accelerate NS002's path to market and reduce development risks.
- Under the new agreements, Aptar France will provide development, testing, and regulatory support for NS002, and will exclusively supply the Unit Dose Powder nasal delivery system (UDSp) devices to Nasus Pharma for its Epinephrine products, subject to FDA approval.
- Nasus Pharma will compensate Aptar France with staged fees over three years, milestone payments upon new drug application (NDA) submission and approval, and royalties from commercial sales for seven years.
Oct 8, 2025, 1:05 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more